

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
6.0	14.04.2025	6097527-00016	Date of first issue: 30.06.2020

Section 1: Identification

Product identifier : Ivermectin Formulation

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

Manufacturer or supplier's details

Company : MSD
Address : 50 Tuas West Drive
Singapore - Singapore 638408
Telephone : +1-908-740-4000
Emergency telephone number : 65 6697 2111 (24/7/365)
E-mail address : EHSDATASTEWARD@msd.com

Section 2: Hazard identification

Classification of the substance or mixture

Specific target organ toxicity - : Category 2 (Central nervous system)
single exposure (Oral)

Specific target organ toxicity - : Category 2 (Central nervous system)
repeated exposure (Oral)

Short-term (acute) aquatic : Category 1
hazard

Long-term (chronic) aquatic : Category 1
hazard

GHS Label elements, including precautionary statements

Hazard pictograms :  

Signal word : Warning

Hazard statements : H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
6.0	14.04.2025	6097527-00016	Date of first issue: 30.06.2020

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

:

Prevention:

P260 Do not breathe mist or vapours.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

Response:

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.

P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture

: Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Ivermectin	70288-86-7	≥ 1 - < 2.5
2,6-Di-tert-butyl-p-cresol	128-37-0	≥ 0.25 - < 1

Section 4: First-aid measures**Description of necessary first-aid measures**

General advice

: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled

: If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact

: Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact

: Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed

: If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
6.0	14.04.2025	6097527-00016	Date of first issue: 30.06.2020

Most important symptoms and effects, both acute and delayed

Risks	: May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment	: Treat symptomatically and supportively.
-----------	---

Section 5: Fire-fighting measures**Extinguishing media**

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
------------------------------	--

Unsuitable extinguishing media	: None known.
--------------------------------	---------------

Special hazards arising from the substance or mixture

Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
---------------------------------------	--

Hazardous combustion products	: Carbon oxides
-------------------------------	-----------------

Special protective actions for fire-fighters

Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
---	--

Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
--------------------------------	---

Section 6: Accidental release measures**Personal precautions, protective equipment and emergency procedures**

Personal precautions	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
----------------------	--

Environmental precautions

Environmental precautions	: Avoid release to the environment.
---------------------------	-------------------------------------

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
6.0	14.04.2025	6097527-00016	06.07.2024
			Date of first issue: 30.06.2020

Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage**Precautions for safe handling**

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage, including any incompatibilities

Conditions for safe storage : Keep in properly labelled containers.

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
6.0	14.04.2025	6097527-00016	06.07.2024
			Date of first issue: 30.06.2020

Materials to avoid : Store locked up.
Store in accordance with the particular national regulations.
Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ivermectin	70288-86-7	TWA	30 µg/m ³ (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	300 µg/100 cm ²	Internal
2,6-Di-tert-butyl-p-cresol	128-37-0	PEL (long term)	10 mg/m ³	SG OEL
		TWA (Inhalable fraction and vapor)	2 mg/m ³	ACGIH

Appropriate engineering control measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the rec-

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
6.0	14.04.2025	6097527-00016	06.07.2024
			Date of first issue: 30.06.2020

Filter type	:	ommended guidelines, use respiratory protection.
Hand protection	:	Particulates type
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.

Section 9: Physical and chemical properties

Appearance	:	oily
Colour	:	light yellow
Odour	:	characteristic
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	167.5 °C
Flash point	:	219.2 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	0.88 - 0.92
Density	:	No data available
Solubility(ies)		
Water solubility	:	practically insoluble
Partition coefficient: n-octanol/water	:	Not applicable

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
6.0	14.04.2025	6097527-00016	06.07.2024
			Date of first issue: 30.06.2020

Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

Section 10: Stability and reactivity

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method

Components:**Ivermectin:**

Acute oral toxicity	:	LD50 (Rat): 50 mg/kg LD50 (Mouse): 25 mg/kg
---------------------	---	--

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
6.0	14.04.2025	6097527-00016	Date of first issue: 30.06.2020

LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Ivermectin:**

Species : Rabbit
Result : No skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Ivermectin:**

Species : Rabbit
Result : Mild eye irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
6.0	14.04.2025	6097527-00016	Date of first issue: 30.06.2020

Result	: No eye irritation
Method	: OECD Test Guideline 405
Remarks	: Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Ivermectin:**

Exposure routes	: Dermal
Species	: Humans
Result	: Does not cause skin sensitisation.

2,6-Di-tert-butyl-p-cresol:

Test Type	: Human repeat insult patch test (HRIPT)
Exposure routes	: Skin contact
Species	: Humans
Result	: negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Ivermectin:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Test system: human diploid fibroblasts Result: negative Test Type: Mouse Lymphoma Result: negative
-----------------------	--

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: In vitro mammalian cell gene mutation test Result: negative Test Type: Chromosome aberration test in vitro Result: negative
-----------------------	---

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
6.0	14.04.2025	6097527-00016	Date of first issue: 30.06.2020

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Ivermectin:**

Species : Rat
Application Route : Oral
NOAEL : 1.5 mg/kg body weight
Result : negative
Remarks : Based on data from similar materials

Species : Mouse
Application Route : Oral
NOAEL : 2.0 mg/kg body weight
Result : negative
Remarks : Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:

Species : Rat
Application Route : Ingestion
Exposure time : 22 Months
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:**Ivermectin:**

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
6.0	14.04.2025	6097527-00016	Date of first issue: 30.06.2020

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

2,6-Di-tert-butyl-p-cresol:

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative

STOT - single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:**Ivermectin:**

Target Organs	: Central nervous system
Assessment	: Causes damage to organs.

STOT - repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Components:**Ivermectin:**

Target Organs	: Central nervous system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

2,6-Di-tert-butyl-p-cresol:

Assessment	: No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.
------------	--

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
6.0	14.04.2025	6097527-00016	Date of first issue: 30.06.2020

Repeated dose toxicity

Components:**Ivermectin:**

Species	: Dog
NOAEL	: 0.5 mg/kg
LOAEL	: 1 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Target Organs	: Central nervous system
Symptoms	: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species	: Monkey
NOAEL	: 1.2 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Remarks	: No significant adverse effects were reported

Species	: Rat
NOAEL	: 0.4 mg/kg
LOAEL	: 0.8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: spleen, Bone marrow, Kidney

2,6-Di-tert-butyl-p-cresol:

Species	: Rat
NOAEL	: 25 mg/kg
Application Route	: Ingestion
Exposure time	: 22 Months

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:**Ivermectin:**

Skin contact	: Remarks: Can be absorbed through skin.
Eye contact	: Remarks: May irritate eyes.
Ingestion	: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
6.0	14.04.2025	6097527-00016	06.07.2024
			Date of first issue: 30.06.2020

Section 12: Ecological information

Toxicity

Components:**Ivermectin:**

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l Exposure time: 96 h LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0.000025 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 10,000
M-Factor (Chronic aquatic toxicity)	: 10,000

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish	: LC50 (Danio rerio (zebra fish)): > 0.57 mg/l Exposure time: 96 h Method: Directive 67/548/EEC, Annex V, C.1.
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0.48 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 1

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
6.0	14.04.2025	6097527-00016	06.07.2024
			Date of first issue: 30.06.2020

Toxicity to fish (Chronic toxicity)	: NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l Exposure time: 30 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.316 mg/l Exposure time: 21 d
M-Factor (Chronic aquatic toxicity)	: 1
Toxicity to microorganisms	: EC50: > 10,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

Persistence and degradability**Components:****Ivermectin:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 240 d
------------------	--

2,6-Di-tert-butyl-p-cresol:

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 4.5 % Exposure time: 28 d Method: OECD Test Guideline 301C
------------------	--

Bioaccumulative potential**Components:****Ivermectin:**

Bioaccumulation	: Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water	: log Pow: 3.22

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation	: Species: Cyprinus carpio (Carp) Bioconcentration factor (BCF): 330 - 1,800
Partition coefficient: n-octanol/water	: log Pow: 5.1

Mobility in soil

No data available

Other adverse effects

No data available

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
6.0	14.04.2025	6097527-00016	Date of first issue: 30.06.2020

Section 13: Disposal considerations**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number	:	UN 3082
UN proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin, 2,6-Di-tert-butyl-p-cresol)
Transport hazard class(es)	:	9
Packing group	:	III
Labels	:	9
Environmental hazards	:	yes

IATA-DGR

UN/ID No.	:	UN 3082
UN proper shipping name	:	Environmentally hazardous substance, liquid, n.o.s. (Ivermectin, 2,6-Di-tert-butyl-p-cresol)
Transport hazard class(es)	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	964
Packing instruction (passenger aircraft)	:	964
Environmentally hazardous	:	yes

IMDG-Code

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin, 2,6-Di-tert-butyl-p-cresol)
Transport hazard class(es)	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
6.0	14.04.2025	6097527-00016	06.07.2024
			Date of first issue: 30.06.2020

Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Section 15: Regulatory information**Safety, health and environmental regulations specific for the product in question**

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subject to the requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable

Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) Regulations : Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 14.04.2025

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average
SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
6.0	14.04.2025	6097527-00016	Date of first issue: 30.06.2020

tem; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN